Concord Medical Services Holdings Limited

What they do

The company operates in the Chinese healthcare market through hospital-based cancer centers and related medical services. Its filing tagging shows revenue split among health care services, medical solutions, and management and technical services. It also holds interests in proton therapy ventures, including entities tied to Beijing Proton Medical Center and US Proton Therapy Holdings, and has divested or restructured some prior hospital assets.

Revenue drivers

• Health care services — One of the tagged revenue lines for 2023-2025, covering patient care services delivered through its hospital and center network in China.
• Medical solutions — A tagged revenue line for 2023-2025, covering equipment and related medical technology solutions provided to hospitals and centers.
• Management and technical services — A tagged revenue line for 2023-2025, covering management and technical support services provided to partner hospitals and centers.
• Proton therapy and hospital investments — The filing references proton therapy holdings and hospital management entities, reflecting the company's investment in higher-cost cancer treatment infrastructure.

Recent performance

Revenue rose to $65.0M in 2025 from $51.3M in 2024, but remained below the $73.3M reported in 2023. The 2025 net loss was $13.3M, a narrower loss than $42.2M in 2024 and $41.9M in 2023. Diluted loss per share improved to $0.10 in 2025 from $0.32 in both 2024 and 2023. Operating cash flow remained negative at -$28.9M in 2025, though less negative than -$54.5M in 2024. Total assets were $936.3M and total liabilities $671.7M at 2025-12-31, leaving shareholders' equity of -$300.7M.

Strategy

The company's filings show activity around restructuring its hospital portfolio, including a 2024 disposal involving Guangzhou Swallowing Home Health Management and New Spring Group. It continues to hold interests in proton therapy entities such as Beijing Proton Medical Center and US Proton Therapy Holdings. Management and technical services remain a tagged revenue line, indicating ongoing service relationships with partner hospitals. The company also reports related-party transactions with entities including Shanghai Changshengshu Management and Shijiazhuang Gaoxin Oncology Hospital.

Risks

• Negative shareholders' equity — Shareholders' equity was -$300.7M at 2025-12-31, with total liabilities of $671.7M against total assets of $936.3M.
• Persistent operating cash burn — Operating cash flow has been negative every year from 2021 through 2025, including -$28.9M in 2025.
• History of net losses — The company reported net losses each year from 2021 through 2025, ranging from $13.3M to $71.0M annually.
• China market and related-party concentration — Revenue is tied to China, and the filings disclose related-party transactions with several affiliated hospital and management entities.

Outlook

The filing excerpts do not include specific forward guidance figures. The most recent reported trend shows 2025 revenue recovering from 2024 and the net loss narrowing, while operating cash flow remained negative. The balance sheet leaves the company with negative shareholders' equity and substantial long-term debt of $352.6M at 2025-12-31.